Pulmicort Budesonide is a white to off-white, tasteless, odorless powder that is practically insoluble in water and in heptane, sparingly soluble in ethanol, and freely soluble in chloroform. Its partition coefficient between octanol and water at pH 7.4 is 1.6 x 103. PULMICORT TURBUHALER is an inhalation-driven multi-dose dry powder inhaler which contains only micronized budesonide. Each actuation of PULMICORT TURBUHALER provides 200 mcg budesonide per metered dose, which delivers approximately 160 mcg budesonide from the mouthpiece based on in vitro testing at 60 L min for 2 sec ; . In vitro testing has shown that the dose delivery for PULMICORT TURBUHALER is substantially dependent on airflow through the device. Patient factors such as inspiratory flow rates will also affect the dose delivered to the lungs of patients in actual use see Patient's Instructions for Use ; . In adult patients with asthma mean FEV1 2.9 L [0.8 - 5.1 L] ; mean peak inspiratory flow PIF ; through PULMICORT TURBUHALER was 78 40-111 ; L min. Similar results mean PIF 82 [43-125] L min ; were obtained in asthmatic children 6 to 15 years, mean FEV1 2.1 L [0.9 - 5.4 L] ; . Patients should be carefully instructed on the use of this drug product to assure optimal dose delivery. Pulmicort respules side effect Determining the effect of HTG on CHD risk was complicated by the close relation of elevated TG with other metabolic abnormalities and the variability in types of HTG, some of which are not linked with accelerating atherosclerosis or increasing risk of premature CHD.10 Early data did not provide strong, consistent evidence for HTG as a cardiovascular risk factor, but in 1988 when the Framingham Heart Study showed a statistically significant relation of elevated TG to CHD in women and elevated TG in 30% of patients with a myocardial infarction MI ; , it became important to understand the impact of one on the other. Triglycerides appear to affect cardiovascular risk in several ways. They are the primary driver of the metabolic disarray of elevated TG, low HDL-C, and small, dense LDL sdLDL ; that characterizes atherogenic dyslipidemia, which plays a major role in overall cardiovascular risk.15 The TG-rich lipoproteins chylomicrons, VLDL, and their remnants appear to be present in atherosclerotic plaque, 16, 17 indicating that the cholesterol in TG-enriched lipoproteins may directly contribute to atherosclerosis. In hypertriglyceridemic patients, TGenriched LDL-C and HDL-C particles become substrates for hepatic lipase, ultimately resulting in increased catabolism of HDL-C and production of the more atherogenic sdLDL. Finally, HTG may contribute to additional pathologic processes associated with MetS and cardiovascular risk, including increased coagulability, impaired fibrinolysis, impaired endothelial function, and increased inflammation, although this remains uncertain.16, 18. The prior coverage authorization procedure has been established solely to determine whether coverage or benefits for Prescription Drugs will be provided under the applicable terms of the policy, contract, or Benefit Booklet. Ultimately, the final decision concerning whether a Prescription Drug should be prescribed must be made by you and the prescribing Physician. Decisions made by us in authorizing coverage are made only to determine whether coverage or benefits are available under the applicable policy, contract, or Benefit Booklet and not for the purpose of providing or recommending care or treatment. Any and all decisions that require or pertain to independent professional medical judgments or training, or the need for a Prescription Drug or Supply, must be made solely by you and your treating Physician in accordance with the patient physician relationship. It is possible that you or your treating Physician may conclude that a particular Prescription Drug or Supply is needed, appropriate, or desirable, even though such Prescription Drug or Supply may not be authorized for coverage by us. In such cases, it is your right and responsibility to decide whether the Prescription Drug or Supply should be purchased even if we have indicated that coverage and payment will not be made for such Prescription Drug or Supply. Pulmicort asthma medicine Xylocaine Injection 1% 10 mg ml ; Change of Name of Manufacturer ; Xylocaine Injection 2% 20 mg ml ; Change of Name of Manufacturer ; Xylocaine adrenaline Injection 1% 10 mg ml + 5 ug ml ; Change of Name of Manufacturer ; Xylocaine adrenaline Injection 2% 20 mg ml + 5 ug ml ; Change of Name of Manufacturer ; Pulicort Suspension for Nebulization 0.25 mg ml Change of Name of Manufacturer ; Pulmicot Suspension for Nebulization 0.5 mg ml Change of Name of Manufacturer ; Marcaine Spinal 0.5 % Heavy Injection 5 mg ml Change of Name of Manufacturer ; Naropin Injection 2 mg ml 0.2% ; Change of Name of Manufacturer ; Naropin Injection 7.5 mg ml 0.75% ; Change of Name of Manufacturer. In August 2006, AstraZeneca received a notice from Dr Reddy's Laboratories Inc. and Dr Reddy's Laboratories Limited together, Dr Reddy's ; that Dr Reddy's had submitted an ANDA to the FDA for esomeprazole magnesium delayed-release capsules, 20mg and 40mg. Dr Reddy's August 2006 notice did not challenge three FDA Orange Book-listed patents claiming esomeprazole magnesium US Patent Nos. 5, 714, 504, and 6, 875, 872 ; . In December 2007, AstraZeneca received another notice from Dr. Reddy's that Dr. Reddy's had submitted an ANDA to the FDA for esomeprazole magnesium delayed-release capsules, 20mg and 40mg. Dissimilar from the August 2006 notice, Dr. Reddy's December 2007 notice did challenge three FDA Orange Book-listed patents claiming esomeprazole magnesium US Patent Nos. 5, 714, 504, and 6, 875, 872 ; . AstraZeneca's exclusivity relating to these three patents expires on 3 August 2015, 27 November 2014 and 27 November 2014, respectively. In January 2008, AstraZeneca commenced patent infringement litigation in the US District Court for the District of New Jersey against Dr. Reddy's in response to Dr. Reddy's Paragraph IV certifications regarding Nexium. No trial date has been set. In July and September 2007, AstraZeneca received notice from Matrix Laboratories, Inc. Matrix ; that Matrix had submitted an ANDA to the FDA for esomeprazole magnesium delayed-release capsules, 20mg and 40mg. Matrix was seeking FDA approval to market a generic esomeprazole magnesium product prior to the expiration of some but not all of the patents listed in the FDA Orange Book with reference to Nexium. Matrix's notice did not challenge three FDA Orange Book-listed patents claiming esomeprazole magnesium US Patent Nos. 5, 714, 504, and 6, 875, 872 ; . Because AstraZeneca has not received notice from Matrix as to these three US patents, Matrix cannot market generic esomeprazole magnesium until the end of the exclusivity afforded by these patents. As a result, AstraZeneca did not bring a lawsuit at this time. AstraZeneca reserves the right to enforce all patents related to Nexium, including those listed in the FDA Orange Book. After its expiry, a 30-month stay will not prevent the FDA from approving an ANDA, and an `at risk' launch by a generic drug manufacturer may occur, of delayed-release esomeprazole magnesium capsules, in the year ending 31 December 2008. In Canada, AstraZeneca Canada, Inc. received several notices of allegation from Apotex Inc. Apotex ; in late 2007 in respect of patents listed on the Patent Register in Canada for Nexium. Apotex has asserted in its notices that it has filed an Abbreviated New Drug Submission in March 2007, for 20mg and 40mg esomeprazole magnesium trihydrate tablets and alleges non-infringement and or invalidity of numerous patents. AstraZeneca has responded by commencing seven court applications in January 2008 under the Patented Medicines Notice of Compliance ; Regulations. On 17 January 2008, Apotex advised that its product was erroneously described as being a trihydrate in its recent allegations, which allegations Apotex asserted it was withdrawing. Apotex mailed replacement allegations on 17 January 2008, which AstraZeneca is entitled to challenge. Apotex cannot obtain a Notice of Compliance marketing approval ; for its esomeprazole tablets until the earlier of the disposition of all of the court applications in Apotex's favour or 24 months from the date on which the latest court application has been commenced. AstraZeneca has full confidence in and will vigorously defend and enforce its intellectual property protecting Nexium. Nolvadex tamoxifen ; AstraZeneca was a co-defendant with Barr Laboratories, Inc. Barr ; in numerous purported class actions filed in federal and state courts throughout the US. All of the state court actions were removed to federal court and were consolidated, along with all of the cases originally filed in the federal courts, in a federal multi-district litigation proceeding pending in the US District Court for the Eastern District of New York. Some of the cases were filed by plaintiffs representing a putative class of consumers who purchased tamoxifen. The other cases were filed on behalf of a putative class of `third party payers' including health maintenance organisations, insurers and other managed care providers and health plans ; that have reimbursed or otherwise paid for prescriptions of tamoxifen. The plaintiffs alleged that they paid `supra-competitive and monopolistic prices' for tamoxifen as a result of the settlement of patent litigation between Zeneca and Barr in 1993. The plaintiffs sought injunctive relief, treble damages under the anti-trust laws, disgorgement and restitution. In April 2002, AstraZeneca filed a motion to dismiss the cases for failure to state a cause of action. In May 2003, the US District Court for the Eastern District of New York granted AstraZeneca's motion to dismiss. The plaintiffs appealed the decision. In November 2005, the US Court of Appeals for the Second Circuit affirmed the District Court's decision. The plaintiffs thereafter moved for re-hearing by the original panel of judges in the case and re-hearing by a panel of all of the judges on the US Court of Appeals for the Second Circuit. The plaintiffs' requests for re-hearing were denied in September 2006. In December 2006, the plaintiffs filed a petition for a writ of certiorari to the US Supreme Court seeking to have the Court hear an appeal of the Second Circuit's decision. In June 2007, the US Supreme Court denied the plaintiffs' writ, thus ending the litigation. Pulm8cort Respules budesonide inhalation suspension ; In September 2005, AstraZeneca received a notice from IVAX Pharmaceuticals Inc. IVAX ; that IVAX had submitted an ANDA to the FDA for a budesonide inhalation suspension containing a Paragraph IV certification and alleging invalidity and non-infringement in respect of certain of AstraZeneca's patents relating to budesonide inhalation suspension. In October 2005, AstraZeneca filed a patent infringement action against IVAX in the US District Court for the District of New Jersey. In December 2005, IVAX responded and filed counterclaims alleging non-infringement and invalidity. In January 2006, AstraZeneca filed an amended complaint, withdrawing averments as to the infringement of one of the patents-in-suit. Discovery in the litigation is ongoing. After its expiry, a 30-month stay will not prevent the FDA from approving an ANDA, and an `at risk' launch by a generic drug manufacturer may occur, of a budesonide inhalation suspension in the year ending 31 December 2008. AstraZeneca continues to have full confidence in and will vigorously defend and enforce its intellectual property protecting Pulmic9rt Respules. NDA 20-441 S-020 Page 8 Patients Previously Maintained on Oral Corticosteroids In a clinical trial in 159 severe asthmatic patients requiring chronic oral prednisone therapy mean baseline prednisone dose 19.3 mg day ; PULMICORT TURBUHALER at doses of 400 mcg twice daily and 800 mcg twice daily was compared with placebo over a 20-week period. Approximately twothirds 68% on 400 mcg twice daily and 64% on 800 mcg twice daily ; of PULMICORT TURBUHALER-treated patients were able to achieve sustained at least 2 weeks ; oral corticosteroid cessation compared with 8% of placebo-treated patients ; and improved asthma control. The average oral corticosteroid dose was reduced by 83% on 400 mcg twice daily and 79% on 800 mcg twice daily for PULMICORT TURBUHALER-treated patients vs. 27% for placebo. Additionally, 58 out of 64 patients 91% ; who completely eliminated oral corticosteroids during the double-blind phase of the trial remained off oral corticosteroids for an additional 12 months while receiving PULMICORT TURBUHALER and medrol. Covered only when mother's life is in jeopardy or when fetus is not viable. Percentage Copayment amounts are based upon PacifiCare's contracted rates. Excludes Ambulance Services. Copayment does not go toward satisfying the Annual Copayment Maximum. Copayment waived if admitted. This Prescription Drug Benefit uses a managed Formulary. All non-Formulary and selected drugs must be preauthorized by PacifiCare. Refer to your Supplement to the Combined Evidence of Coverage and Disclosure Form for Severe Mental Illness SMI ; and Serious Emotional Disturbances of Children SED ; for coverage details. Percentage Copayment amounts are based upon PacifiCare's Limited Fee Schedule. Excludes Ambulance Services. The ongoing market research indicate, the potential for growth, despite challenges of competition from the soft drinks and other beverages, specially in the Urban markets. Hence, an optimistic consumption growth rate of 7% in the case of arabica and 13% in the case of robusta is envisaged with a base level of 55, 000 tonnes as depicted in Table 14.5 Table 14.5 X Plan Domestic Consumption targets for Coffee Qty. in Tonnes and in million bags in brackets ; Year 2002-03 2003-04 2004-05 RUBBER Natural rubber has been attaining highest growth rate in term of production, productivity and expansion of area. The production and productivity of natural rubber increased from 15, 830 tonnes and 284 kg ha in 1950-51 to 635000 tonnes and 1576 kg ha at the end of 2001, respectively. The expected production of rubber by the end of X plan would reach to the level of 717000 tonnes. The targets for X plan production and consumption are given in table 14.6. Table 14.6 X Plan Domestic Consumption targets of NR in India Year 2002-03 2003-04 2004-05 Production 660 678 694 Consumption 683 717 752 000 tonnes ; Gap Production Consumption ; -23 -39 -58 -84 -113 Arabica Growth rate 7% ; 38000 0.63 ; 41000 0.68 ; 44000 0.73 ; 47000 0.78 ; 50000 0.83 ; Robusta Growth rate 13% ; 23000 0.38 ; 26000 0.43 ; 30000 0.50 ; 35000 0.58 ; 40000 0.66 ; 61, 000 1.02 ; 67, 000 1.12 ; 74, 000 1.23 ; 82, 000 1.37 ; 90, 000 1.50 and alavert. H: \Data\Asthma\National Final\PUF2\create formatted frequencies national.lst Asthma National Interview File Variables In Alphabetical Order The CONTENTS Procedure --Alphabetic List of Variables and Attributes -# Variable Type Len Pos Format Label 179 S8Q16R 24 Num 8 1400 PERMONF. HOW LONG BEEN TAKING PROVENTIL? WOULD YOU SAY LESS THAN 6 MONTHS, 6 MONTHS TO 1 YEAR, OR LONGER THAN 1 YEAR? 180 S8Q16R 25 Num 8 1408 PERMONF. HOW LONG BEEN TAKING PULMICORT TURBUHALER? WOULD YOU SAY LESS THAN 6 MONTHS, 6 MONTHS TO 1 YEAR, OR LONGER THAN 1 YEAR? 181 S8Q16R 26 Num 8 1416 PERMONF. HOW LONG BEEN TAKING SALMETEROL? WOULD YOU SAY LESS THAN 6 MONTHS, 6 MONTHS TO 1 YEAR, OR LONGER THAN 1 YEAR? 182 S8Q16R 27 Num 8 1424 PERMONF. HOW LONG BEEN TAKING SEREVENT? WOULD YOU SAY LESS THAN 6 MONTHS, 6 MONTHS TO 1 YEAR, OR LONGER THAN 1 YEAR? 183 S8Q16R 28 Num 8 1432 PERMONF. HOW LONG BEEN TAKING TERBUTALINE? WOULD YOU SAY LESS THAN 6 MONTHS, 6 MONTHS TO 1 YEAR, OR LONGER THAN 1 YEAR? 184 S8Q16R 29 Num 8 1440 PERMONF. HOW LONG BEEN TAKING TILADE? WOULD YOU SAY LESS THAN 6 MONTHS, 6 MONTHS TO 1 YEAR, OR LONGER THAN 1 YEAR? 185 S8Q16R 30 Num 8 1448 PERMONF. HOW LONG BEEN TAKING TORNALATE? WOULD YOU SAY LESS THAN 6 MONTHS, 6 MONTHS TO 1 YEAR, OR LONGER THAN 1 YEAR? 186 S8Q16R 31 Num 8 1456 PERMONF. HOW LONG BEEN TAKING TRIAMCINOLONE ACETONIDE? WOULD YOU SAY LESS THAN 6 MONTHS, 6 MONTHS TO 1 YEAR, OR LONGER THAN 1 YEAR? 187 S8Q16R 32 Num 8 1464 PERMONF. HOW LONG BEEN TAKING VANCERIL? WOULD YOU SAY LESS THAN 6 MONTHS, 6 MONTHS TO 1 YEAR, OR LONGER THAN 1 YEAR? 188 S8Q16R 33 Num 8 1472 PERMONF. HOW LONG BEEN TAKING VENTOLIN? WOULD YOU SAY LESS THAN 6 MONTHS, 6 MONTHS TO 1 YEAR, OR LONGER THAN 1 YEAR? 189 S8Q16R 34 Num 8 1480 PERMONF. HOW LONG BEEN TAKING [OTHER INHALER]? WOULD YOU SAY LESS THAN 6 MONTHS, 6 MONTHS TO 1 YEAR, OR LONGER THAN 1 YEAR? 190 S8Q17R 01 Num 8 1488 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH ADVAIR? 191 S8Q17R 02 Num 8 1496 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH AEROBID? 192 S8Q17R 03 Num 8 1504 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH ALBUTEROL? 193 S8Q17R 04 Num 8 1512 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH ALUPENT? 194 S8Q17R 05 Num 8 1520 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH ATROVENT? 195 S8Q17R 06 Num 8 1528 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH AZMACORT? 196 S8Q17R 07 Num 8 1536 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH BECLOMETHASONE DIPROPIONATE? 197 S8Q17R 08 Num 8 1544 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH BECLOVENT? 198 S8Q17R 09 Num 8 1552 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH BITOLTEROL? 199 S8Q17R 10 Num 8 1560 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH BRETHAIRE? 200 S8Q17R 11 Num 8 1568 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH BUDESONIDE? 201 S8Q17R 12 Num 8 1576 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH COMBIVENT? 202 S8Q17R 13 Num 8 1584 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH CROMOLYN? 203 S8Q17R 14 Num 8 1592 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH FLOVENT? 204 S8Q17R 15 Num 8 1600 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH FLOVENT ROTADISK? 205 S8Q17R 16 Num 8 1608 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH FLUNISOLIDE? 206 S8Q17R 17 Num 8 1616 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH FLUTICASONE? 207 S8Q17R 18 Num 8 1624 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH INTAL? 208 S8Q17R 19 Num 8 1632 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH IPRATROPIUM BROMIDE? 209 S8Q17R 20 Num 8 1640 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH MAXAIR? 210 S8Q17R 21 Num 8 1648 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH METAPROTERONOL? 211 S8Q17R 22 Num 8 1656 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH NEDOCROMIL? 212 S8Q17R 23 Num 8 1664 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH PIRBUTEROL? 213 S8Q17R 24 Num 8 1672 YESNOF. A SPACER IS A SMALL ATTACHMENT FOR AN INHALER THAT MAKES IT EASIER TO USE. USE A SPACER WITH PROVENTIL? 15: 09 Friday, September 23, 2005 18. Inaddition, one of the side effects of pulmicort inhaling that i know of isgagging in the morning so he dislikes eating his breakfast and this mighteffects his school performance because he lacks energy and clarinex. The following charts include influenza vaccination rates from nursing homes homes for the aged, hospitals, and retirement homes. The Ministry target is to have at least 70% of staff and 95% of residents vaccinated. To minimize the systemic effects of inhaled corticosteroids, including PULMICORT RESPULES, each patient should be titrated to his her lowest effective dose. Geriatric Use Of the 215 patients in 3 clinical trials of PULMICORT RESPULES in adult patients, 65 30% ; were 65 years of age or older, while 22 10% ; were 75 years of age or older. No overall differences in safety were observed between these patients and younger patients, and other reported clinical or medical surveillance experience has not identified differences in responses between the elderly and younger patients. ADVERSE REACTIONS The following adverse reactions were reported in pediatric patients treated with PULMICORT RESPULES. The incidence of common adverse reactions is based on three double-blind, placebo-controlled, U.S. clinical trials in which 945 patients, 12 months to 8 years of age, 98 patients 12 months and 2 years of age; 225 patients 2 and 4 years of age; and 622 patients 4 and 8 years of age ; were treated with PULMICORT RESPULES 0.25 to 1 mg total daily dose for 12 weeks ; or vehicle placebo. The incidence and nature of adverse events reported for PULMICORT RESPULES was comparable to that reported for placebo. The following table shows the incidence of adverse events in U.S. controlled clinical trials, regardless of relationship to treatment, in patients previously receiving bronchodilators and or inhaled corticosteroids. This population included a total of 605 male and 340 female patients and periactin. DISCUSSION Turbuhaler ; , and Budesonide Inhaled Suspension Pulmicotr Respules ; 7 and over only ; . No public comment. Ms. Kroeger had some concerns with requiring a PA for Pulmicort Respules for nursing home patients. Usually when she starts a patient on inhaled corticosteroids, she wants them to start ASAP, it is not logical to have to wait 24 hours before the prescription can be filled. Mary stated that we could make nursing home patients exempt from PA for that drug. Dr. Burke asked if the drugs are on the shelf in a nursing home. Ms. Kroger stated that it depends on the nursing home, but usually you have to send the prescription to a pharmacy and then they bring it to you. Deb stated that if Ms. Kroger already had the PA forms that she could fill out her portion and then send it to the pharmacist to speed up the process. Deb also pointed out that PAs are approved within 24 hours, but it is usually less time than that. If everything is filled out correctly and it is within business hours the PA can be approved within 5 minutes. Anne asked if it would be possible to exempt nursing home patients from the PA process on Pulmicort Respules. Karen said that it would be possible, the system could be set up to allow patients 6 and under and nursing home patients exemption from the PA process on Pulmicort Respules. Mary stated that the effective date for the Medicare Modernization Act MMA ; will be January 1, 2006. Therefore, the time and cost to change the system to allow exemption from PA for Pulmicort Respules for nursing home patients would not be feasible. Energy Savings in Lube Oil Packaging: Tin Cans vs HDPE Cans Unit Tin Cans Material Required MT 86207 Energy Required for Manufacturing Cans 000 GJ 7484 Total No. of Truck loads Required No. 120690 4.7 times that of Energy Required for Distribution HDPE cans Energy Required for 100% Recycling GJ 1602 Total Energy Required GJ 9086.7 Note: For packaging of 1 MMT Lube Oil Source: LCA, IIT Delhi HDPE Cans 63218 6526 118135 and entocort. Congressional Hearing: Current Issues Related to Medical Liability Reform 2 10 05 pooling risk and making sure all doctors have coverage, Wisconsin has successfully addressed this issue, and these actions controlled malpractice costs long before Wisconsin capped non-economic damage. This brings me to my final point. state issue. This should be a. PHARMACY REFERRAL GUIDELINE INHALED STEROIDS Formulary Alternatives Budesonide Pulmicort Turbohaler ; Fluticasone Flovent ; Triamcinolone Azmacort ; Use by Age 2 years old: can use Pulmicort Respules . Requires prior authorization for 2 years of age or older. 2-5 years old: Flovent with mask or spacer 5 years old: any formulary alternative and zaditor. NEBULIZER USAGE GUIDELINES AND CARE OF YOUR NEBULIZER continued ; CLEANING NEEDED ONCE OR TWICE A WEEK 1. Remove the mask or the mouthpiece and T-shaped part from the cup. Remove the tubing and set it aside. The tubing should not be washed or rinsed. Wash the mask or the mouthpiece and T-shaped part with a mild dishwashing soap and warm water. 2. Rinse under a strong stream of water for 30 seconds. 3. Soak for 30 minutes in a solution that is one part distilled white vinegar and two parts distilled water. Throw out the vinegar water solution after use; do not reuse it. 4. Rinse the nebulizer parts under warm running water for 1 minute. 5. Shake off excess water. Air dry on a clean cloth or paper towel. 6. Disconnect the tubing from the compressed air machine. Store the nebulizer in a ziploc plastic bag. 7. Clean the surface of the compressed air machine with a well-wrung, soapy cloth or sponge. You could also use an alcohol or disinfectant wipe. NEVER PUT THE COMPRESSED AIR MACHINE IN WATER TYPES OF MEDICATIONS USED IN NEBULIZER AND PROPER PREPARATIONS 1. ALBUTEROL - This comes n a unit dose vial if used by itself or comes in a multidose bottle if used in combination with other meds Cromolyn Sodium or Atrovent ; . The recommended dose of Albuterol in the multidose vial is .25 ml for infants and small children and .50 ml for older children and adults. If the multidose bottle is used in the .25 ml or .50 ml dose you must dilute the medication with 2 cc's of saline solution. Otherwise there would not be enough liquid in the cup to nebulize. 2. ATROVENT - This comes in a unit dose vial. It can be used alone or in combination with Albuterol to get a potentiated effect. If Atrovent is used in combination with Albuterol, use Albuterol in the multidose bottle in prescribed dose and also add 1 unit dose vial of Atrovent to nebulizer cup. 3. CROMOLYN SODIUM - This comes in a unit dose vial. It can also be used alone or in combination with Albuterol. If it is used in combination with Albuterol, use the Albuterol in the multidose bottle in prescribed dose and add 1 unit dose vial of Cromolyn Sodium to nebulizer cup. 4. PULMICORT RESPULES - This must be given by a Pari Jet nebulizer, tubing and Pari mask. The mask must be tight fitting over the face and medicine must not get into eyes. This medicine cannot be given by a blow by method as some other medicines are. You must wash the face and mouth out after each treatment so as not to get a fungal infection. The medicine is light sensitive and must be kept in the foil package. It can be given in combination with albuterol if needed. It comes in .25 or .50 dosages and is usually given once per day, but use as directed by your physician. It is the only anti-inflammatory medication which can be given via nebulizer. Effects of pulmicort in children Summary of Drug Limitations PREVIDENT 5000 PLUS CREAM PRIMAXIN 500 mg VIAL PRIMAXIN I.M. PRIMAXIN I.V. 250 mg VIAL PROPOXY-N-APAP 100-650 TAB Protonix 20mg PROTONIX 40 mg TABLET EC PROZAC 20mg PULVULE PROZAC WEEKLY 90 mg CAPSULE PULMICORT 200 MCG TURBUHALE RANITIDINE 300 mg CAPSULE RANITIDINE 300 mg TABLET REBETRON REGRANEX 0.01% GEL RELENZA INHALER Relpax 20 mg Tablet Relpax 40 mg Tablet RESCON MX TABLET RESPIGAM 50 mg ml VIAL RHINOCORT NASAL INHALER RHO D ; IMMUNE GLOBULIN RISPERDAL CONSTA SYR ROCEPHIN KIT ROCEPHIN KIT SEASONALE 0.15 0.03 mg TAB SEDATIVE-HYPNOTICS, NON-BARBITURATE SEREVENT 21 MCG INHALER SEROQUEL 25 mg TABLET SINGULAIR Smoking deterrents SPORANOX 250 mg KIT Sular 20mg, 20mg SYMBYAX CAPSULE SYMBYAX CAPSULE SYMBYAX CAPSULE Maximum of 51GM per dispensing Maximum of 16 vials per day Maximum of 6 vials per day Maximum of 32 vials per day Maximum of 12 tablets per day Limited to 1 dose per day maximum of 2 tablets per day Maximum of 8 capsules per day Maximum of 4 capsules per month Maximum of 1 inhaler every 24 days Maximum of 2 capsules per day Maximum of 2 tablets per day Maximum of 3 kits per dispensing Maximum of 15GM per dispensing and 140 days of therapy per year nursing home recipients require Prior Authorization ; Patient must be at least 6 and a maximum of 3 prescriptions per year 6 per 28 6 per 28 Recipient must be under 21 years of age Recipient must be 3 years of age, may dispense up to 8 prescription per year. Maximum of maximum of 3 inhalers per month Female only, maximum of 2 syringes per dispensing and 4 prescription per year Maximum of 8 syringes per month Maximum of 4 kits per day Maximum of 4 vials per day Female only, recipient must be over the age of 12. Maximum of 1 tablet per day. May dispense a 91 day supply Maximum of 45 units every 25 days Maximum of 2 inhalers per month Maximum of 12 tablets per day Maximum of 1 tablet per day 84 days of therapy per year recipient must be 16 or older ; Maximum of 20 per month Limited to 1 dose per day Recipient must be over the age of 2 and daily dose must be 1 Capsule per day Recipient must be over the age of 2 and daily dose must be 1 Capsule per day Recipient must be over the age of 2 and daily dose must be 1 Capsule per day and zyrtec. City of Milwaukee Choice Plan - Police Association Therapeutic Interchange List Note: Suggested interchange is product appropriate for MOST indications. Last Updated * 1 2008 Non-Preferred Not Covered Alternative * ACCOLATE SINGULAIR ACCUNEB albuterol neb. solution ACTIVELLA FEMHRT PREMPRO FOSAMAX ACTONEL AEROBID FLOVENT PULMICORT ALESSE aviane lessina lutera ALLEGRA loratadine OTC ALORA CLIMARA VIVELLE DOT ALTACE benazepril captopril enalapril lisinopril ALTOPREV CRESTOR LESCOL LESCOL XL lovastatin simvastatin VYTORIN AMANTADINE TAB amantadine cap AMBIEN CR temazepam trazodone zolpidem AMRIX cyclobenzaprine ANA-KIT INJ EPIPEN ANDEHIST DM OTC Alternatives ANDRODERM ANDROGEL ANDROID ANDROGEL ANGELIQ COMBIPATCH FEMHRT PREMPHASE PREMPRO ANZEMET ondansetron APIDRA NOVOLOG AQUATAB D OTC Alternatives ARISTOCORT-A triamcinolone ARIXTRA FRAGMIN LOVENOX ARTHROTEC PRILOSEC OTC + generic NSAID AT LAST BLOOD GLUCOSE SYS ACCU-CHEK METER FREESTYLE METER PRECISION XTRA METER ATROVENT Nasal Spray ipratropium bromide nasal spray AUGMENTIN XR amoxicillin clavulamic acid Augmentin Equiv ; AURALGAN OTIC antipyrine benzocaine. SAMS specialized agencies and marketing services ; : Berlex Campath, The Diabetes Consortium and Bertek Asimia by Nelson Communications, Watson Pharmaceuticals Oxytrol, AstraZeneca Rhinocort, Pulmicort and Symbicort by the Medicus Group, Pfizer Aricept - Pfizer Pharmacia Xalatan by Manning, Selvage & Lee. It should be noted that the trend of significant new business for the Groupe's agency networks continued strong in April and May to date. This included Publicis Worldwide's gain of Allied Domecq's global account for spirits, including advertising as well as other communications services, Starcom MediaVest Group's gain of the Gateway media account, and ZenithOptimedia's win of Miramax's media account and singulair. In a transparent and speedy manner. Citizens could get most of the services as well as information online, including building approvals, payment of taxes, public health, and engineering, municipal budget allocations, tax payment, grievance registration and monitoring, birth and death certificates. Rent for advertising space was calculated automatically, removing discretion and introducing transparency. In just one year, 2002, the system issued 15, 000 birth and death certificates, 2, 100 building approvals, and 224, 000 demand notices for taxes. Of the 7, 700 grievances that were registered, 97% were resolved. This project has reduced corruption, made services more accessible, and improved the finances of local governments Kumar and Bhatnagar 2001, worldbank , CMC Limited 2004, Government of Andhra Pradesh 2005. 10. Ibid. The FDA's Center for Biologics Evaluation and Research does require that the product be intended for a serious or life-threatening disease or condition to receive a priority review. 11. A mechanism of action is the way the drug affects a biological pathway by acting on a biological structure or system to achieve a desired outcome. 12. Doctor's Guide, "FDA Approves Gleevec Imatinib Mesylate ; for Leukemia Treatment, " Washington, D.C. May 10, 2001 ; , accessed March 6, 2002 from : docguide . 13. Doctor's Guide, "FDA Approves Pulmicort Nebulized Corticosteroid Budesonide ; For Asthmatic Children, " Wayne, PA August 2000 ; , accessed January 21, 2002 from docguide . Cf. also fda.gov. 14. Doctor's Guide, "FDA Approves Aggrenox for Patients With Previous Strokes, " Ridgefield, CT November 23, 1999 ; . Accessed March 5, 2002 from : docguide . 15. As mentioned above, the ranking system used by the FDA until 1992 distinguished among three classes of new drugs. The present system, which the FDA began to use in 1992, recognizes only two classes of drugs, priority and standard. The priority class comprises both the A ; and B ; groups of the older ranking system, thus including medicines that would formerly have been viewed as offering moderate improvements. 16. In a September 17, 2001 warning letter to Raymond V. Gilmartin, President and CEO of Merck, the FDA notes that in the Vioxx Gastrointestinal Outcomes Research VIGOR ; study, "patients on Vioxx were observed to have a four to five fold increase in myocardial infarctions MIs ; compared to patients on the comparator non-steroidal anti-inflammatory drug NSAID ; , Naprosyn naproxen ; ." Accessed March 30, 2002 from fda.gov. 17. Drugs using the same mechanism of action affect the same biological pathway by acting on the same biological structure or system in a similar way, thus achieving the same outcome. Such drugs are often said to be in the same therapeutic class. 18. This number excludes an increase in three priority approvals for other drugs, which would bring the total increase in priority approvals to 30. 19. Kaiser Family Foundation and the NIHCM Foundation. 20. F.R. Lichtenberg, "Are the Benefits of Newer Drugs Worth Their Cost? Evidence From The 1996 MEPS, " Health Affairs Sept Oct 2001 ; : 241251. 21. K.A. Getz and A. De Bruin, "Breaking the Development Speed Barrier: Assessing Successful Practices of the Fastest Drug Development Companies, " Drug Information Journal, Vol. 34 2000 ; : 725. 22. Pfizer 2001 revenue is taken from the company's "2001 Fourth Quarter Earnings Release, " accessed from pfizer . Merck's 2001 revenue is taken from Standard & Poor's Stock Reports, "Merck, " March 4, 2002 ; , accessed from agedwards . 23. J.A. DiMasi, PhD, "New Drug Innovation and Pharmaceutical Industry Structure: Trends in the Output of Pharmaceutical Firms, " Drug Information Journal, Vol. 34 2000 ; : 11691194. 24. IMS Health, "IMS HEALTH Data Reveal Dramatic Growth in Megabrands, " no date, accessed March 25, 2002 from : imshealth . 25. Estimates of the combined value of drugs going off patent vary, depending on the methodology and time horizon used. Last year, some industry analysts projected that the principal patents on branded drugs with collective sales of about billion would expire by 2005, and that about billion would do so by 2010. Cf. J.I. Treppel, "Generic Drugs: Where Are We Now? Where and lexapro and Order pulmicort. The primary analysis of efficacy will use the intent-to-treat principle, in which all randomized subjects who receive study drug will be included. If appropriate, a secondary analysis of efficacy will exclude subjects who have significant protocol violations or take rescue medication prior to the 20-minute time point. 8.9 SAFETY ANALYSIS. Considering these results, we hypothesized that an ARB has antiatherosclerotic effects via inhibiting TNF -RAGE interaction, thus leading to the decrease in the inflammatory process of atherosclerosis. We tested this hypothesis using human endothelial cells and tofranil. Test to tree pollens, six patients had a positive reaction to week pollen, and five patients had a positive reaction to house dust mite. No patient had received oral corticosteroids or antibiotics for 6 mo before the study. All patients were nonsmokers and had normal full blood count, biochemical profile, and urinalysis. Approval for the study was obtained from the Tayside Medical Ethics Committee and all patients gave their written informed consent. The study was of a randomized placebo-controlled, single-blind, double-dummy, crossover design Table 1 ; . Patients were recruited during June and July 1999 when grass pollen levels are typically high in Tayside. Patients were randomized to receive the following treatments for 2 wk, all given once daily at 8: 00 A.M.: 1 ; 400 g inhaled budesonide dry powder Pulmicort Turbuhaler; Astra Zeneca, Kings Langley, Herts, UK as 2 puffs of 200 g per actuation ; plus 200 g intranasal aqueous budesonide Rhinocort Aqua; Astra Pharmaceuticals Ltd, as 1 squirt of 100 g in each nostril ; BUD ; plus placebo tablets; or 2 ; 10 mg oral montelukast Singulair; Merck Sharpe & Dohme Ltd, Herts, UK ; and 10 mg oral cetirizine Zirtek; UCB Pharma, Watford, Herts, UK ; ml CZ ; plus placebo nasal spray and placebo Turbuhaler. Before each treatment, and at crossover, patients had a 1-wk washout period with placebo Turbuhaler 2 inhalations ; , placebo nasal spray 1 squirt in each nostril ; , and placebo tablets all taken at 8: 00 A.M. The Turbuhalers and nasal sprays were masked and sealed in envelopes by a pharmacist along with instruction sheets at the beginning of the trial. Before the study and at each visit, patients were given detailed instruction by a third party in how to use their nasal sprays and Turbuhaler. Nasal sprays were primed according the manufacturers' instructions and patients had to demonstrate adequate technique using Turbuhaler usage trainer Astra Draco, Lund, Sweden ; before progressing through the study. Each patient received a written instruction sheet, based on manufacturers' recommendations, to follow while taking their medication at home, and a simple tick chart was used as an aid to compliance. Data from patients with more than 90% compliance were considered to be evaluable. Ngiotensin II Ang II ; is an octapeptide that acts at different sites in the brain eg, the vascular, neuroendocrine, and behavioral systems ; . Angiotensin converting enzyme ACE ; , which converts Ang I to Ang II, is expressed in cerebral microvessels of the rat1 suggesting local formation of Ang II in addition to circulating Ang II. In cerebral vessels, Ang II has been found to induce vasoconstriction2, 3 and vasodilatation, 4 depending on the species studied and methods used. The responses to Ang II are predominantly mediated by the Ang II type 1 AT1 ; and type 2 AT2 ; receptor subtypes, of which the AT1 receptor subtype mediates contraction of cerebral arteries in adult rats.5 The present study is based on the hypothesis that cerebral ischemia induces a change in local vascular receptor expression and function, which might influence the ischemia and have a role in the development of the penumbral zone. In a previous study, we revealed an upregulation of contractile endothelin type B ETB ; receptors with enhanced transcription in the middle cerebral artery MCA ; of the rat 48 hours after temporal MCA occlusion.6 In the present study we used the same experimental model. The functional responses to Ang II in the MCA were examined by myographs, and the relative mRNA. Like all medicines, Karvea can cause side effects, although not everybody gets them. Some of these effects may be serious and may require medical attention. The frequency of the side effects listed below is defined using the following convention: Very common: at least 1 in 10 patients or more Common: at least 1 in 100 and less than 1 in 10 patients Uncommon: at least 1 in 1000 and less than 1 in 100 patients Side effects reported in clinical studies for patients treated with Karvea were: Common: dizziness, feeling sick vomiting, and fatigue. In patients with high blood pressure and type 2 diabetes with renal disease, dizziness when getting up from a lying or sitting position, low blood pressure when getting up from a lying or sitting position, and pain in joints or muscles were also reported. Uncommon: heart rate increased, flushing, cough, diarrhoea, indigestion heartburn, sexual dysfunction problems with sexual performance ; , chest pain. In addition your doctor may identify abnormal changes in your blood components such as creatine kinase increased common ; . Moreover, if you suffer from high blood pressure and type 2 diabetes with renal disease, your doctor may identify the following changes in your blood components: potassium increased very common ; , haemoglobin decreased common ; . Some undesirable effects have been reported since marketing of Karvea but the frequency for them to occur is not known. These undesirable effects are: headache, taste disturbance, ringing in the ears, muscle cramps, pain in joints and muscles, liver function abnormal, increased blood potassium levels, impaired renal function, and inflammation of small blood vessels mainly affecting the skin a condition known as leukocytoclastic vasculitis ; . As with similar medicines, rare cases of allergic skin reactions rash, urticaria ; , as well as localised swelling of the face, lips and or tongue have been reported in patients taking irbesartan. If you think you are developing such a reaction or get short of breath stop taking Karvea and seek immediate medical attention. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. 5. HOW TO STORE KARVEA. Everyday activities do not produce enough `strain' to change bone mass, so resistance exercises need to be increased as the body adapts to each new level. This can be done by: increasing the resistance; changing the exercise so that a new strain pattern begins; or when it starts to feel easy, you need to increase the weight. 4 Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These may include adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma. 4.9 Overdose The only harmful effect that follows inhalation of large amounts of the drug over a short period is suppression of hypothalamic-pituitary-adrenal HPA ; function. No special emergency action needs to be taken. Treatment with Pulmicort LS Inhaler should be continued at the recommended dose to control the asthma and buy medrol. Pulmicort inhaler dose The administration of inhaled budesonide via a different dry-powder inhaler in doses up to 800 mcg day mean daily dose 445 mcg day ; or via a pressurized metered-dose inhaler in doses up to 1200 mcg day mean daily dose 620 mcg day ; to 216 pediatric patients age 3 to 11 years ; for 2 to 6 years had no significant effect on statural growth compared with non-corticosteroid therapy in 62 matched control patients. However, the long-term effect of inhaled budesonide on growth is not fully known. Clinical Studies The safety and efficacy of PULMICORT FLEXHALER were evaluated in two 12-week, double-blind, randomized, parallel-group, placebo-controlled clinical studies conducted at sites in the United States and Asia involving 1137 patients aged 6 to 80 years with mild to moderate asthma. Study 1 evaluated PULMICORT FLEXHALER 180 mcg, PULMICORT TURBUHALER 200 mcg, and placebo, each administered as 1 inhalation once daily or 2 inhalations twice daily in patients 18 years of age and older with mild to moderate asthma previously treated with inhaled corticosteroids. The delivered dose of PULMICORT FLEXHALER 180 mcg and PULMICORT TURBUHALER 200 mcg are the same; each delivers 160 mcg from the mouthpiece. Study 2 evaluated PULMICORT FLEXHALER 90 mcg, 2 inhalations once daily or 4 inhalations twice daily, PULMICORT TURBUHALER 200 mcg, 1 inhalation once daily or 2 inhalations twice daily, and placebo in pediatric patients aged 6 to 17 years with mild to moderate asthma. Both of the studies had a 2-week placebo treatment run-in period followed by a 12-week randomized treatment period. The primary endpoint was the difference between baseline and the mean of the treatment-period FEV1 adults ; or FEV1 % predicted children. Pulmicort flexhaler prescribing information Pulmicotr, pulmucort, pulmico4t, puomicort, pulmiccort, p7lmicort, pulnicort, pulmic9rt, pulmico5t, pullmicort, pulmivort, lulmicort, pumicort, pulmicor6, pulmickrt, pulmicor5, pulmiort, pulmiicort, pulmicoft, pulmicrot, pulmicrt, pulmidort, pulmicortt, pulmicorrt, pulmicogt, uplmicort, pulmjcort, pulmicoet, pulm9cort, pulmlcort, pulmicor, pilmicort, pulicort, pulmkcort, pulmiclrt, pukmicort. Pulmicort nebules dosage Pulmicort respules side effect, pulmicort asthma medicine, effects of pulmicort in children, pulmicort inhaler dose and pulmicort flexhaler prescribing information. Pulmicort nebules dosage, pulmicort mask for nebulizer, long term effects of using pulmicort and budesonide vs pulmicort or pulmicort stunting growth. Pulmicort mask for nebulizer Passive aggressive supervisor, internal resorption extraction, mycelex bayer, physical growth quotes and proinflammatory chemokines. Tremor lighting, spectrum orthopaedics canton ohio, causes of macrocytic red blood cells and baby yeast diaper rash monistat or repetitive stress injury claims. © 2006-2008 Lynx.freewebhostx.com -All Rights Reserved.